SOPHIRIS BIO INC. SEC Filings

If this box is checked, additional Borrowers ("Additional Borrowers") are listed in the Annex attached hereto (Borrower and such Additional Borrowers, collectively, "Borrower").

Sophiris Bio Inc. will not complete its financial audit for the year-ended December 31, 2019 in an effort to conserve its cash resources. The Company has not filed, nor is it planning to file its Annual Report on Form 10-K for the year-e...

We have read the statements made by Sophiris Bio Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Sophiris Bio Inc. dated March 31, 2020. We agree w...

SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 – Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage c...

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Granted 103,000 Common Stock (Right to Buy) ($37.1K)

Granted 175,000 Common Stock (Right to Buy) ($63K)

Granted 123,000 Common Stock (Right to Buy)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

SAN DIEGO and VANCOUVER, British Columbia, November 7, 2019 – Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treat...

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As reported in the Original Current Report, at the Annual Meeting, a majority of the Company’s shareholders that voted on proposal 3 indicated a preference to hold, on an advisory basis, the Company’s future say-on-pay advisory vote on a...